On April 1, 2024 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation in an upcoming investor relations event (Press release, Ideaya Biosciences, APR 1, 2024, View Source [SID1234641678]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel Virtual Targeted Oncology Forum
Tuesday, April 16th, 2024 at 12:00 PM ET

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Benjamin Burnett, Ph.D., Managing Director, Equity Analyst
A live audio webcast of conference event, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at View Source and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.

On April 1, 2024 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation in an upcoming investor relations event (Press release, Ideaya Biosciences, APR 1, 2024, View Source [SID1234641678]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel Virtual Targeted Oncology Forum
Tuesday, April 16th, 2024 at 12:00 PM ET

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Benjamin Burnett, Ph.D., Managing Director, Equity Analyst
A live audio webcast of conference event, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at View Source and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.

On April 1, 2024 DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, reported multiple upcoming poster and oral presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place in San Diego, California, from April 5-10, 2024 (Press release, Delfi Diagnostics, APR 1, 2024, View Source [SID1234641677]). DELFI and independent researchers will highlight the performance of the company’s next-generation, fragmentomics-based liquid biopsy platform to help detect early cancer and monitor treatment response.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"DELFI’s robust presence at AACR (Free AACR Whitepaper) this year reflects our substantial clinical progress in demonstrating the DELFI platform’s high performance in a range of applications across multiple tumor types," said Susan Tousi, DELFI Chief Executive Officer. "We’re excited to share additional clinical validation data for FirstLook Lung, the first and only screening test of its kind for early lung cancer detection, as we actively expand commercial partnerships with select U.S. health systems. Patients need better cancer screening and treatment-monitoring options, while health systems and payers need affordable and broadly accessible tests that improve patient outcomes. Our multiple datasets at AACR (Free AACR Whitepaper) will showcase DELFI’s expansive and differentiated potential in these areas."

DELFI will be located at AACR (Free AACR Whitepaper) Booth 947. Individual session details follow:

Presenter

Title

Session Title

Session
Date

Session
Time

Location

Poster
Board
Number

Published
Abstract
Number

Rob
Scharpf

Models and Prediction

ED01 – Data Science Opportunities and Challenges in Biomarker-based Early Detection of Cancer

4/6/2024

8:30 AM-8:50 AM

Ballroom 6 CF – Upper Level

NA

NA

Rob
Scharpf

NA

ED01 – Data Science Opportunities and Challenges in Biomarker-based Early Detection of Cancer

4/6/2024

8:00 AM- 9:30 AM

Ballroom 6 CF – Upper Level

NA

NA

Lindsey
Cotton

Clinical validation: A blood-based biomarker for early lung cancer detection based on circulating DNA fragmentomics

Early Detection Biomarkers I

4/7/2024

1:30-5PM

Poster Section 43

10

1062

Peter
Bach

Projected impact of liquid biopsy screening strategies with high sensitivity in focused populations and high specificity in broad populations

Multi-Cancer Early Detection Testing: Where Are We?

4/7/2024

4:05 PM – 4:20 PM

Room 28 – Upper Level

N/A

1267

Stephen Cristiano

Robustness of fragmentation-based cell-free DNA approaches to clonal hematopoiesis

Circulating Nucleic Acids 1

4/7/2024

1:30 PM – 5:00 PM

Poster Section 40

22

981

Akshaya Annapragada

Genome-wide repeat landscapes in cancer and cell-free DNA

Circulating Nucleic Acids 1

4/7/2024

1:30 PM – 5:00 PM

Poster Section 40

29

988

Carlie
Hruban

Liquid biopsy approaches for monitoring metastatic pancreatic cancer in immunotherapy treated patients

Circulating Nucleic Acids 2

4/8/2024

9:00 AM – 12:30 PM

Poster Section 40

18

2422

Bahar Alipanahi

Monitoring response to immunotherapy using cell-free DNA fragmentomes

Circulating Tumor Cells 1

4/8/2024

1:30 PM – 5:00 PM

Poster Section 42

7

3695

Denise
Van
Steijn

Monitoring treatment response in patients with metastatic colorectal cancer using cfDNA fragmentomics testing: the DOLPHIN trial

Circulating Nucleic Acids 3

4/8/2024

1:30-5PM

Poster Section 41

18

3673

Victor Velculescu

Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers

Press Conference

4/9/2024

8:30 AM

Room 26

NA

NA

Nick
Vulpescu

Chromatin landscapes of colorectal cancer development and cfDNA fragmentation

Characterization of Mutational Processes and Drivers in Cancer Development and Evolution

4/9/2024

9:00 AM – 12:30 PM

Poster Section 15

9

4339

Victor Velculescu

Early detection of cancer using cell-free DNA fragmentomes

AT07 – New Liquid Biopsy Technologies for Detection and Characterization of Cancer

4/9/2024

1:25 PM – 1:45 PM

Ballroom 20 CD – Upper Level

NA

NA

Victor Velculescu

NA

AT07 – New Liquid Biopsy Technologies for Detection and Characterization of Cancer

4/9/2024

12:30 PM – 2:00 PM

Ballroom 20 CD – Upper Level

NA

NA

Jamie
Medina
and
Akshaya Annapragada

Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers

Biomarker-Based Screening

4/9/2024

1:30 PM – 5:00 PM

Poster Section 31

12

6086

On April 1, 2024 Biolexis Therapeutics, Inc. a clinical-stage biopharmaceutical company with a novel AI-assisted drug discovery platform technology, reported it will present five posters at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper), taking place April 5-10, 2024, in San Diego, CA (Press release, Biolexis Therapeutics, APR 1, 2024, View Source [SID1234641676]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AACR poster presentation details are below:

Title: "Discovery of an oral, potent, and selective CDK9 molecular glue degrader SLX-3065 active in aggressive variant prostate cancers (AVPC)"
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Session Date and Time: Monday Apr 8, 2024 1:30 PM – 5:00 PM
Location: Poster Section 52
Poster Board Number: 7
Abstract Presentation Number: LB161
Presenter: Chenyu Lin

Title: "BLX-3030, a potent, selective, orally available small molecule CDK9 inhibitor for aggressive variant prostate cancers"
Session Category: Experimental and Molecular Therapeutics
Session Title: New Compounds and Drug Targets
Session Date and Time: Tuesday Apr 9, 2024 9:00 AM – 12:30 PM
Location: Poster Section 27
Poster Board Number: 2
Abstract Presentation Number: 4649
Presenter: Zhaoliang Li

Title: "Development of highly selective, potent, orally available PIM1 inhibitor BLX0631 shows a therapeutics potential in multiple myeloma models"
Session Category: Experimental and Molecular Therapeutics
Session Title: HDAC and Methyltransferase Inhibitors
Session Date and Time: Tuesday Apr 9, 2024 9:00 AM – 12:30 PM
Location: Poster Section 24
Poster Board Number: 9
Abstract Presentation Number: 4587
Presenter: Kyle Medley

Title: "Identification of a novel and selective Transglutaminase 2 (TGM2) inhibitors modulate tumor microenvironment in Glioblastoma"
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 4
Session Date and Time: Wednesday Apr 10, 2024 9:00 AM – 12:30 PM
Location: Poster Section 54
Poster Board Number: 20
Abstract Presentation Number: LB444
Presenter: Hariprasad Vankayalapati

Biolexis & TGen Collaboration
Title: "Development of a novel ATP-competitive CDK9 inhibitor for treatment of pancreatic cancer"
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Biologic Therapies and Therapeutics Targets
Session Date and Time: Tuesday Apr 9, 2024 1:30 PM – 5.00 PM
Location: Poster Section 27
Poster Board Number: 5
Abstract Presentation Number: 5957
Presenter: Yesenia Barrera-Millan & Haiyong Han

More information can be found on the AACR (Free AACR Whitepaper) meeting website.

On April 1, 2024 Turbine, a company that is building the world’s first predictive simulation of patient biology, and Harmonic Discovery (Harmonic), a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, reported to have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine’s Simulated Cell platform (Press release, Harmonic Discovery, APR 1, 2024, View Source [SID1234641675]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We believe that the dark kinase NEK1 holds great potential as a drug target for developing cancer therapies addressing important resistance challenges in the clinic," said Daniel Veres, M.D., Ph.D., Chief Scientific Officer and Co-Founder of Turbine. "Coupling Harmonic’s deep expertise in multi-specific kinase-targeted drug design with our unique ability to guide drug discovery by running simulated experiments with causal interpretation in a vast biological search space will help realize a more innovative and efficient process than traditional approaches. We are excited for the opportunity to demonstrate the power of our platforms to collectively boost R&D success in the clinic."

"Our fully integrated kinase drug discovery platform aims to challenge current drug discovery paradigms by building a machine learning-first infrastructure that integrates multiple aspects of kinase drug discovery," said Rayees Rahman, Ph.D., CEO and Co-Founder of Harmonic Discovery. "Turbine’s exciting biological simulation technology is highly complementary to our approach. We are confident that integrating both companies’ innovative platforms will yield a radically more effective approach to selecting and advancing kinase-targeted therapies that can substantially improve patient outcomes in oncology."

The collaboration provides a framework in which biological and mechanistic insights from Turbine’s simulations will directly inform Harmonic’s generative chemistry models – with the goal of bringing forward new, differentiated, and effective kinase inhibitor therapies for the patients who need them most. Harmonic will assume responsibilities for computational chemistry and medicinal chemistry activities, while Turbine will be responsible for in silico simulations and wet-lab validation of target biology, including the identification of both synergistic kinase co-targets to NEK1 and patient populations most likely to benefit from therapies. Financial terms of the collaboration are not disclosed.